An anti-ER “Riptac” enters phase 1.
ApexOnco Front Page
Recent articles
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
Though lung cancer looks promising a partner is now needed.
The company’s AN9025 will shortly enter phase 1.
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
But the group still hopes to get IGV-001 approved based on overall survival data.
A more comprehensive dataset on JANX007 sends the group’s stock down.
